Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04278131 · ClinicalTrials.gov registry record · Phase 1
BS01 in Patients With Retinitis Pigmentosa
A Phase 1 study of Retinitis Pigmentosa, sponsored by Bionic Sight.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04278131: Recruiting Phase 1 study of Retinitis Pigmentosa, sponsored by Bionic Sight.
NCT04278131 is a Phase 1 study of Retinitis Pigmentosa that is actively recruiting participants, run by Bionic Sight. The registered enrollment target is 20 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04278131, a Phase 1 study of Retinitis Pigmentosa, is actively recruiting participants, sponsored by Bionic Sight.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Primary Outcome
Number of subjects with adverse events, changes in hematology/chemistry
Conditions Studied
Interventions
- DRUG BS01
Study Locations (1)
New Jersey
- New Jersey Retina - Teaneck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2029-12-30 |
| Phase | Phase 1 |
What NCT04278131 shows while recruiting
NCT04278131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which BS01 is the first listed.
NCT04278131 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04278131 about?
NCT04278131 is a clinical study titled "BS01 in Patients With Retinitis Pigmentosa". A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
What is the current status of trial NCT04278131?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-02-06. Estimated completion is 2029-12-30.
What conditions does trial NCT04278131 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT04278131?
The interventions under investigation include: BS01 (DRUG).
Who is sponsoring clinical trial NCT04278131?
This trial is sponsored by Bionic Sight, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04278131 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04278131's enrollment target sits among peer trials
20 26th of 37 higher than 11 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC for the Treatment of RP
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI